Report Detail

Pharma & Healthcare COVID-19 Impact on Global Varicella Live Vaccine Market Insights, Forecast to 2026

  • RnM4071400
  • |
  • 22 June, 2020
  • |
  • Global
  • |
  • 145 Pages
  • |
  • QYResearch
  • |
  • Pharma & Healthcare

Varicella Live Vaccine market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Varicella Live Vaccine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Varicella Live Vaccine market is segmented into
Monovalent Vaccines
Multivalent Vaccines

Segment by Application, the Varicella Live Vaccine market is segmented into
Chicken Pox Immunization
Herpes Zoster Immunization
Measles Immunization
Others

Regional and Country-level Analysis
The Varicella Live Vaccine market is analysed and market size information is provided by regions (countries).
The key regions covered in the Varicella Live Vaccine market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Varicella Live Vaccine Market Share Analysis
Varicella Live Vaccine market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Varicella Live Vaccine business, the date to enter into the Varicella Live Vaccine market, Varicella Live Vaccine product introduction, recent developments, etc.
The major vendors covered:
Astellas Pharma Inc.
CSL Limited
Emergent BioSolutions, Inc.
GlaxoSmithKline plc
Johnson & Johnson
MedImmune, LLC
Merck & Co., Inc.
Pfizer, Inc.
Sanofi Pasteur
Serum Institute of India Pvt. Ltd.
Bavarian Nordic
Mitsubishi Tanabe Pharma Corporation
Daiichi Sankyo
Biological E
Panacea Biotec


1 Study Coverage

  • 1.1 Varicella Live Vaccine Product Introduction
  • 1.2 Market Segments
  • 1.3 Key Varicella Live Vaccine Manufacturers Covered: Ranking by Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Varicella Live Vaccine Market Size Growth Rate by Type
    • 1.4.2 Monovalent Vaccines
    • 1.4.3 Multivalent Vaccines
  • 1.5 Market by Application
    • 1.5.1 Global Varicella Live Vaccine Market Size Growth Rate by Application
    • 1.5.2 Chicken Pox Immunization
    • 1.5.3 Herpes Zoster Immunization
    • 1.5.4 Measles Immunization
    • 1.5.5 Others
  • 1.6 Coronavirus Disease 2019 (Covid-19): Varicella Live Vaccine Industry Impact
    • 1.6.1 How the Covid-19 is Affecting the Varicella Live Vaccine Industry
      • 1.6.1.1 Varicella Live Vaccine Business Impact Assessment - Covid-19
      • 1.6.1.2 Supply Chain Challenges
      • 1.6.1.3 COVID-19’s Impact On Crude Oil and Refined Products
    • 1.6.2 Market Trends and Varicella Live Vaccine Potential Opportunities in the COVID-19 Landscape
    • 1.6.3 Measures / Proposal against Covid-19
      • 1.6.3.1 Government Measures to Combat Covid-19 Impact
      • 1.6.3.2 Proposal for Varicella Live Vaccine Players to Combat Covid-19 Impact
  • 1.7 Study Objectives
  • 1.8 Years Considered

2 Executive Summary

  • 2.1 Global Varicella Live Vaccine Market Size Estimates and Forecasts
    • 2.1.1 Global Varicella Live Vaccine Revenue 2015-2026
    • 2.1.2 Global Varicella Live Vaccine Sales 2015-2026
  • 2.2 Varicella Live Vaccine Market Size by Region: 2020 Versus 2026
    • 2.2.1 Global Varicella Live Vaccine Retrospective Market Scenario in Sales by Region: 2015-2020
    • 2.2.2 Global Varicella Live Vaccine Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Varicella Live Vaccine Competitor Landscape by Players

  • 3.1 Varicella Live Vaccine Sales by Manufacturers
    • 3.1.1 Varicella Live Vaccine Sales by Manufacturers (2015-2020)
    • 3.1.2 Varicella Live Vaccine Sales Market Share by Manufacturers (2015-2020)
  • 3.2 Varicella Live Vaccine Revenue by Manufacturers
    • 3.2.1 Varicella Live Vaccine Revenue by Manufacturers (2015-2020)
    • 3.2.2 Varicella Live Vaccine Revenue Share by Manufacturers (2015-2020)
    • 3.2.3 Global Varicella Live Vaccine Market Concentration Ratio (CR5 and HHI) (2015-2020)
    • 3.2.4 Global Top 10 and Top 5 Companies by Varicella Live Vaccine Revenue in 2019
    • 3.2.5 Global Varicella Live Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Varicella Live Vaccine Price by Manufacturers
  • 3.4 Varicella Live Vaccine Manufacturing Base Distribution, Product Types
    • 3.4.1 Varicella Live Vaccine Manufacturers Manufacturing Base Distribution, Headquarters
    • 3.4.2 Manufacturers Varicella Live Vaccine Product Type
    • 3.4.3 Date of International Manufacturers Enter into Varicella Live Vaccine Market
  • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Varicella Live Vaccine Market Size by Type (2015-2020)
    • 4.1.1 Global Varicella Live Vaccine Sales by Type (2015-2020)
    • 4.1.2 Global Varicella Live Vaccine Revenue by Type (2015-2020)
    • 4.1.3 Varicella Live Vaccine Average Selling Price (ASP) by Type (2015-2026)
  • 4.2 Global Varicella Live Vaccine Market Size Forecast by Type (2021-2026)
    • 4.2.1 Global Varicella Live Vaccine Sales Forecast by Type (2021-2026)
    • 4.2.2 Global Varicella Live Vaccine Revenue Forecast by Type (2021-2026)
    • 4.2.3 Varicella Live Vaccine Average Selling Price (ASP) Forecast by Type (2021-2026)
  • 4.3 Global Varicella Live Vaccine Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End

5 Breakdown Data by Application (2015-2026)

  • 5.1 Global Varicella Live Vaccine Market Size by Application (2015-2020)
    • 5.1.1 Global Varicella Live Vaccine Sales by Application (2015-2020)
    • 5.1.2 Global Varicella Live Vaccine Revenue by Application (2015-2020)
    • 5.1.3 Varicella Live Vaccine Price by Application (2015-2020)
  • 5.2 Varicella Live Vaccine Market Size Forecast by Application (2021-2026)
    • 5.2.1 Global Varicella Live Vaccine Sales Forecast by Application (2021-2026)
    • 5.2.2 Global Varicella Live Vaccine Revenue Forecast by Application (2021-2026)
    • 5.2.3 Global Varicella Live Vaccine Price Forecast by Application (2021-2026)

6 North America

  • 6.1 North America Varicella Live Vaccine by Country
    • 6.1.1 North America Varicella Live Vaccine Sales by Country
    • 6.1.2 North America Varicella Live Vaccine Revenue by Country
    • 6.1.3 U.S.
    • 6.1.4 Canada
  • 6.2 North America Varicella Live Vaccine Market Facts & Figures by Type
  • 6.3 North America Varicella Live Vaccine Market Facts & Figures by Application

7 Europe

  • 7.1 Europe Varicella Live Vaccine by Country
    • 7.1.1 Europe Varicella Live Vaccine Sales by Country
    • 7.1.2 Europe Varicella Live Vaccine Revenue by Country
    • 7.1.3 Germany
    • 7.1.4 France
    • 7.1.5 U.K.
    • 7.1.6 Italy
    • 7.1.7 Russia
  • 7.2 Europe Varicella Live Vaccine Market Facts & Figures by Type
  • 7.3 Europe Varicella Live Vaccine Market Facts & Figures by Application

8 Asia Pacific

  • 8.1 Asia Pacific Varicella Live Vaccine by Region
    • 8.1.1 Asia Pacific Varicella Live Vaccine Sales by Region
    • 8.1.2 Asia Pacific Varicella Live Vaccine Revenue by Region
    • 8.1.3 China
    • 8.1.4 Japan
    • 8.1.5 South Korea
    • 8.1.6 India
    • 8.1.7 Australia
    • 8.1.8 Taiwan
    • 8.1.9 Indonesia
    • 8.1.10 Thailand
    • 8.1.11 Malaysia
    • 8.1.12 Philippines
    • 8.1.13 Vietnam
  • 8.2 Asia Pacific Varicella Live Vaccine Market Facts & Figures by Type
  • 8.3 Asia Pacific Varicella Live Vaccine Market Facts & Figures by Application

9 Latin America

  • 9.1 Latin America Varicella Live Vaccine by Country
    • 9.1.1 Latin America Varicella Live Vaccine Sales by Country
    • 9.1.2 Latin America Varicella Live Vaccine Revenue by Country
    • 9.1.3 Mexico
    • 9.1.4 Brazil
    • 9.1.5 Argentina
  • 9.2 Central & South America Varicella Live Vaccine Market Facts & Figures by Type
  • 9.3 Central & South America Varicella Live Vaccine Market Facts & Figures by Application

10 Middle East and Africa

  • 10.1 Middle East and Africa Varicella Live Vaccine by Country
    • 10.1.1 Middle East and Africa Varicella Live Vaccine Sales by Country
    • 10.1.2 Middle East and Africa Varicella Live Vaccine Revenue by Country
    • 10.1.3 Turkey
    • 10.1.4 Saudi Arabia
    • 10.1.5 U.A.E
  • 10.2 Middle East and Africa Varicella Live Vaccine Market Facts & Figures by Type
  • 10.3 Middle East and Africa Varicella Live Vaccine Market Facts & Figures by Application

11 Company Profiles

  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Astellas Pharma Inc. Corporation Information
    • 11.1.2 Astellas Pharma Inc. Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Inc. Varicella Live Vaccine Products Offered
    • 11.1.5 Astellas Pharma Inc. Recent Development
  • 11.2 CSL Limited
    • 11.2.1 CSL Limited Corporation Information
    • 11.2.2 CSL Limited Description, Business Overview and Total Revenue
    • 11.2.3 CSL Limited Sales, Revenue and Gross Margin (2015-2020)
    • 11.2.4 CSL Limited Varicella Live Vaccine Products Offered
    • 11.2.5 CSL Limited Recent Development
  • 11.3 Emergent BioSolutions, Inc.
    • 11.3.1 Emergent BioSolutions, Inc. Corporation Information
    • 11.3.2 Emergent BioSolutions, Inc. Description, Business Overview and Total Revenue
    • 11.3.3 Emergent BioSolutions, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.3.4 Emergent BioSolutions, Inc. Varicella Live Vaccine Products Offered
    • 11.3.5 Emergent BioSolutions, Inc. Recent Development
  • 11.4 GlaxoSmithKline plc
    • 11.4.1 GlaxoSmithKline plc Corporation Information
    • 11.4.2 GlaxoSmithKline plc Description, Business Overview and Total Revenue
    • 11.4.3 GlaxoSmithKline plc Sales, Revenue and Gross Margin (2015-2020)
    • 11.4.4 GlaxoSmithKline plc Varicella Live Vaccine Products Offered
    • 11.4.5 GlaxoSmithKline plc Recent Development
  • 11.5 Johnson & Johnson
    • 11.5.1 Johnson & Johnson Corporation Information
    • 11.5.2 Johnson & Johnson Description, Business Overview and Total Revenue
    • 11.5.3 Johnson & Johnson Sales, Revenue and Gross Margin (2015-2020)
    • 11.5.4 Johnson & Johnson Varicella Live Vaccine Products Offered
    • 11.5.5 Johnson & Johnson Recent Development
  • 11.6 MedImmune, LLC
    • 11.6.1 MedImmune, LLC Corporation Information
    • 11.6.2 MedImmune, LLC Description, Business Overview and Total Revenue
    • 11.6.3 MedImmune, LLC Sales, Revenue and Gross Margin (2015-2020)
    • 11.6.4 MedImmune, LLC Varicella Live Vaccine Products Offered
    • 11.6.5 MedImmune, LLC Recent Development
  • 11.7 Merck & Co., Inc.
    • 11.7.1 Merck & Co., Inc. Corporation Information
    • 11.7.2 Merck & Co., Inc. Description, Business Overview and Total Revenue
    • 11.7.3 Merck & Co., Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.7.4 Merck & Co., Inc. Varicella Live Vaccine Products Offered
    • 11.7.5 Merck & Co., Inc. Recent Development
  • 11.8 Pfizer, Inc.
    • 11.8.1 Pfizer, Inc. Corporation Information
    • 11.8.2 Pfizer, Inc. Description, Business Overview and Total Revenue
    • 11.8.3 Pfizer, Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.8.4 Pfizer, Inc. Varicella Live Vaccine Products Offered
    • 11.8.5 Pfizer, Inc. Recent Development
  • 11.9 Sanofi Pasteur
    • 11.9.1 Sanofi Pasteur Corporation Information
    • 11.9.2 Sanofi Pasteur Description, Business Overview and Total Revenue
    • 11.9.3 Sanofi Pasteur Sales, Revenue and Gross Margin (2015-2020)
    • 11.9.4 Sanofi Pasteur Varicella Live Vaccine Products Offered
    • 11.9.5 Sanofi Pasteur Recent Development
  • 11.10 Serum Institute of India Pvt. Ltd.
    • 11.10.1 Serum Institute of India Pvt. Ltd. Corporation Information
    • 11.10.2 Serum Institute of India Pvt. Ltd. Description, Business Overview and Total Revenue
    • 11.10.3 Serum Institute of India Pvt. Ltd. Sales, Revenue and Gross Margin (2015-2020)
    • 11.10.4 Serum Institute of India Pvt. Ltd. Varicella Live Vaccine Products Offered
    • 11.10.5 Serum Institute of India Pvt. Ltd. Recent Development
  • 11.1 Astellas Pharma Inc.
    • 11.1.1 Astellas Pharma Inc. Corporation Information
    • 11.1.2 Astellas Pharma Inc. Description, Business Overview and Total Revenue
    • 11.1.3 Astellas Pharma Inc. Sales, Revenue and Gross Margin (2015-2020)
    • 11.1.4 Astellas Pharma Inc. Varicella Live Vaccine Products Offered
    • 11.1.5 Astellas Pharma Inc. Recent Development
  • 11.12 Mitsubishi Tanabe Pharma Corporation
    • 11.12.1 Mitsubishi Tanabe Pharma Corporation Corporation Information
    • 11.12.2 Mitsubishi Tanabe Pharma Corporation Description, Business Overview and Total Revenue
    • 11.12.3 Mitsubishi Tanabe Pharma Corporation Sales, Revenue and Gross Margin (2015-2020)
    • 11.12.4 Mitsubishi Tanabe Pharma Corporation Products Offered
    • 11.12.5 Mitsubishi Tanabe Pharma Corporation Recent Development
  • 11.13 Daiichi Sankyo
    • 11.13.1 Daiichi Sankyo Corporation Information
    • 11.13.2 Daiichi Sankyo Description, Business Overview and Total Revenue
    • 11.13.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
    • 11.13.4 Daiichi Sankyo Products Offered
    • 11.13.5 Daiichi Sankyo Recent Development
  • 11.14 Biological E
    • 11.14.1 Biological E Corporation Information
    • 11.14.2 Biological E Description, Business Overview and Total Revenue
    • 11.14.3 Biological E Sales, Revenue and Gross Margin (2015-2020)
    • 11.14.4 Biological E Products Offered
    • 11.14.5 Biological E Recent Development
  • 11.15 Panacea Biotec
    • 11.15.1 Panacea Biotec Corporation Information
    • 11.15.2 Panacea Biotec Description, Business Overview and Total Revenue
    • 11.15.3 Panacea Biotec Sales, Revenue and Gross Margin (2015-2020)
    • 11.15.4 Panacea Biotec Products Offered
    • 11.15.5 Panacea Biotec Recent Development

12 Future Forecast by Regions (Countries) (2021-2026)

  • 12.1 Varicella Live Vaccine Market Estimates and Projections by Region
    • 12.1.1 Global Varicella Live Vaccine Sales Forecast by Regions 2021-2026
    • 12.1.2 Global Varicella Live Vaccine Revenue Forecast by Regions 2021-2026
  • 12.2 North America Varicella Live Vaccine Market Size Forecast (2021-2026)
    • 12.2.1 North America: Varicella Live Vaccine Sales Forecast (2021-2026)
    • 12.2.2 North America: Varicella Live Vaccine Revenue Forecast (2021-2026)
    • 12.2.3 North America: Varicella Live Vaccine Market Size Forecast by Country (2021-2026)
  • 12.3 Europe Varicella Live Vaccine Market Size Forecast (2021-2026)
    • 12.3.1 Europe: Varicella Live Vaccine Sales Forecast (2021-2026)
    • 12.3.2 Europe: Varicella Live Vaccine Revenue Forecast (2021-2026)
    • 12.3.3 Europe: Varicella Live Vaccine Market Size Forecast by Country (2021-2026)
  • 12.4 Asia Pacific Varicella Live Vaccine Market Size Forecast (2021-2026)
    • 12.4.1 Asia Pacific: Varicella Live Vaccine Sales Forecast (2021-2026)
    • 12.4.2 Asia Pacific: Varicella Live Vaccine Revenue Forecast (2021-2026)
    • 12.4.3 Asia Pacific: Varicella Live Vaccine Market Size Forecast by Region (2021-2026)
  • 12.5 Latin America Varicella Live Vaccine Market Size Forecast (2021-2026)
    • 12.5.1 Latin America: Varicella Live Vaccine Sales Forecast (2021-2026)
    • 12.5.2 Latin America: Varicella Live Vaccine Revenue Forecast (2021-2026)
    • 12.5.3 Latin America: Varicella Live Vaccine Market Size Forecast by Country (2021-2026)
  • 12.6 Middle East and Africa Varicella Live Vaccine Market Size Forecast (2021-2026)
    • 12.6.1 Middle East and Africa: Varicella Live Vaccine Sales Forecast (2021-2026)
    • 12.6.2 Middle East and Africa: Varicella Live Vaccine Revenue Forecast (2021-2026)
    • 12.6.3 Middle East and Africa: Varicella Live Vaccine Market Size Forecast by Country (2021-2026)

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

  • 13.1 Market Opportunities and Drivers
  • 13.2 Market Challenges
  • 13.3 Market Risks/Restraints
  • 13.4 Porter’s Five Forces Analysis
  • 13.5 Primary Interviews with Key Varicella Live Vaccine Players (Opinion Leaders)

14 Value Chain and Sales Channels Analysis

  • 14.1 Value Chain Analysis
  • 14.2 Varicella Live Vaccine Customers
  • 14.3 Sales Channels Analysis
    • 14.3.1 Sales Channels
    • 14.3.2 Distributors

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Research Methodology
      • 16.1.1 Methodology/Research Approach
      • 16.1.2 Data Source

    Summary:
    Get latest Market Research Reports on COVID-19 Impact on Global Varicella Live Vaccine. Industry analysis & Market Report on COVID-19 Impact on Global Varicella Live Vaccine is a syndicated market report, published as COVID-19 Impact on Global Varicella Live Vaccine Market Insights, Forecast to 2026. It is complete Research Study and Industry Analysis of COVID-19 Impact on Global Varicella Live Vaccine market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,900.00
    $5,850.00
    $7,800.00
    3,014.70
    4,522.05
    6,029.40
    3,630.90
    5,446.35
    7,261.80
    595,491.00
    893,236.50
    1,190,982.00
    329,160.00
    493,740.00
    658,320.00
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report